Shots:

• Genentech reports the new data for Enspryng on reducing relapse severity in the treatment of neuromyelitis optical spectrum disorder (NMOSD)- to be presented at MSVirtual2020.
• In a pos-thoc analysis- 79% reduction in relapse severity by vs PBO (19% vs 35%) in P-III SAkura studies. Pooled data from Sakura OLE studies support the continued effect of Enspryng reducing the risk of relapse in the longer term by 51% and showed more effect in AQP4-IgG seropositive patients i.e. 66% reduction in risk of relapse
• Enspryng is the 1^st and only FDA-approved SC- self-administered medicine for NMOSD and the 1^st medicine for NMOSD which targets the IL-6 receptor- approved in Canada- Japan- Switzerland- and the US. Additionally- it has received the US FDA’s BT designation for NMOSD in Dec’2018

­ Ref: Genentech | Image: Life Science Review